PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Non-Synonymous Mutation Analysis in SARS-CoV-2 Variants Isolated from Humans and Prediction of Conserved Linear Antibody Epitopes for Use in Country-wise Epitope-Based Vaccine Development
Version 1
: Received: 3 June 2020 / Approved: 4 June 2020 / Online: 4 June 2020 (05:50:09 CEST)
How to cite:
Kumar, P.; Sharma, K.; Khan, N.N.; Sana, H.B.; Khan, M.A. Non-Synonymous Mutation Analysis in SARS-CoV-2 Variants Isolated from Humans and Prediction of Conserved Linear Antibody Epitopes for Use in Country-wise Epitope-Based Vaccine Development. Preprints2020, 2020060024. https://doi.org/10.20944/preprints202006.0024.v1
Kumar, P.; Sharma, K.; Khan, N.N.; Sana, H.B.; Khan, M.A. Non-Synonymous Mutation Analysis in SARS-CoV-2 Variants Isolated from Humans and Prediction of Conserved Linear Antibody Epitopes for Use in Country-wise Epitope-Based Vaccine Development. Preprints 2020, 2020060024. https://doi.org/10.20944/preprints202006.0024.v1
Kumar, P.; Sharma, K.; Khan, N.N.; Sana, H.B.; Khan, M.A. Non-Synonymous Mutation Analysis in SARS-CoV-2 Variants Isolated from Humans and Prediction of Conserved Linear Antibody Epitopes for Use in Country-wise Epitope-Based Vaccine Development. Preprints2020, 2020060024. https://doi.org/10.20944/preprints202006.0024.v1
APA Style
Kumar, P., Sharma, K., Khan, N.N., Sana, H.B., & Khan, M.A. (2020). Non-Synonymous Mutation Analysis in SARS-CoV-2 Variants Isolated from Humans and Prediction of Conserved Linear Antibody Epitopes for Use in Country-wise Epitope-Based Vaccine Development. Preprints. https://doi.org/10.20944/preprints202006.0024.v1
Chicago/Turabian Style
Kumar, P., Hamza Bin Sana and Mohammad Ali Khan. 2020 "Non-Synonymous Mutation Analysis in SARS-CoV-2 Variants Isolated from Humans and Prediction of Conserved Linear Antibody Epitopes for Use in Country-wise Epitope-Based Vaccine Development" Preprints. https://doi.org/10.20944/preprints202006.0024.v1
Abstract
COVID-19 pandemic has caused a large-scale havoc in almost every country across the globe, putting major challenges for the healthcare system in many parts of the world. Several of the laboratories are running in the race with undying efforts for developing potential vaccine, drugs or therapeutics to treat or prevent the infection. However, with the limited time window and high rate of infection, the task is very big for humanity to find a cure. With hundreds of genomic data of SARS-CoV-2 virus isolates from humans are being submitted almost every day, it is coming into knowledge that virus is mutating, slower in countries with sporadic cases, but higher in countries experiencing large outbreak. These types of mutations in virus may bring challenges in vaccine or therapeutic development for use in each and every country, as each hotspot region may have their own pattern of mutations in virus with ongoing outbreak. In our current study, we retrieved non-synonymous mutation data of around 12,225 SARS-CoV-2 virus samples isolated from humans globally, and discovered all mutations that are collectively happening in antibody epitope regions of the virus country-wise. We found a few numbers of epitope regions in SARS-CoV-2 that are highly conserved collectively in all variants and may be used for epitope-based vaccine development for whole world. We also found epitope regions that are conserved collectively in SARS-CoV-2 variants country-wise and can be used for customized epitope-based vaccine development in each different country.
Keywords
SARS-CoV-2; Mutations; Epitope; Vaccine
Subject
Biology and Life Sciences, Virology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
